Product acquisition – regenerative medicine
​Collagen Solutions is a biomaterials company developing and manufacturing medical grade collagen components for use in medical devices, regenerative medicine, and in vitro diagnostic products. It supplies value-added bio-functional collagen, provides R&D and contract manufacturing services to a broad range of clients, ranging from research organisations to multi-national corporates and, with this acquisition, now has the option of selling a regenerative medical product into the orthobiologics market, thereby capturing a greater share of the end-product margin. The addressable market for this product is in excess of $500m.
Collagen Solutions is a holding company. Through its subsidiaries, Co. is engaged in the supply, development and manufacture of medical-grade collagen components and biomaterials for use in regenerative medicine, medical devices and in-vitro diagnostics. Co.'s primary products include medical-grade collagen, the primary protein in those tissues that provides a supportive environment for the cells, and processed native tissues such as pericardium, a tissue that surrounds the heart, and medical-grade collagen formulations. Co. supplies these as standard raw materials as well as in custom formulations that are used for the basic research to regenerative medicine therapies and medical devices.
We are a rapidly growing, innovative corporate research & consultancy business, based in London, serving the needs of both public and private companies.
Our expert team of sector analysts and market professionals collectively have over 400 years of experience. This depth of knowledge and a reputation for integrity have built trust with investors. With effective communication and precision distribution, we help companies disseminate their investment message to interested investors, as well as advise them on strategy.
Our smaller, boutique structure allows us to provide first-class customer service and to deliver a wide range of ad-hoc services for multiple clients with different needs.
Unfortunately, this report is not available for the investor type or country you selected.
Browse all ResearchPool reportsReport is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.